Thermo Fisher Scientific TMO Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Consolidated revenues by Business | ||||||
| Analytical Instruments | $7.55B0.0% | $7.55B+0.4% | $7.53B+1.1% | $7.44B-0.7% | $7.49B+0.4% | |
| Laboratory Products and Biopharma Services | $24.38B+1.7% | $23.98B+1.9% | $23.54B+1.0% | $23.31B— | —— | |
| Life Sciences Solutions | $10.67B+2.8% | $10.37B+3.4% | $10.03B+2.0% | $9.83B+1.5% | $9.69B+0.6% | |
| Specialty Diagnostics | $4.67B-0.1% | $4.68B+1.4% | $4.61B+1.0% | $4.57B+0.4% | $4.55B+0.9% | |
| Cost of revenues by Business | ||||||
| Analytical Instruments | $3.89B+1.1% | $3.85B+3.6% | $3.72B+2.7% | $3.62B— | —— | |
| Laboratory Products and Biopharma Services | $18.96B+1.9% | $18.61B+1.9% | $18.26B+0.7% | $18.12B— | —— | |
| Life Sciences Solutions | $4.08B+3.8% | $3.93B+5.8% | $3.72B+1.5% | $3.66B— | —— | |
| Specialty Diagnostics | $2.7B-0.8% | $2.72B+1.2% | $2.69B+0.5% | $2.67B— | —— | |
| Operating Income (Loss) by Business | ||||||
| Analytical Instruments | $1.69B-2.5% | $1.74B-4.6% | $1.82B-1.2% | $1.84B-5.8% | $1.96B-0.1% | |
| Laboratory Products and Biopharma Services | $3.4B+1.4% | $3.35B+3.0% | $3.25B+3.0% | $3.16B— | —— | |
| Life Sciences Solutions | $3.89B+3.2% | $3.77B+2.6% | $3.67B+3.5% | $3.55B+1.6% | $3.5B-0.2% | |
| Specialty Diagnostics | $1.27B+0.7% | $1.26B+4.2% | $1.21B+2.4% | $1.18B+0.7% | $1.17B+0.9% | |
| Other segment items by Business | ||||||
| Analytical Instruments | $152M+0.7% | $151M-6.2% | $161M+2.5% | $157M— | —— | |
| Laboratory Products and Biopharma Services | -$429M-1.7% | -$422M-9.6% | -$385M+2.3% | -$394M— | —— | |
| Life Sciences Solutions | $218M+2.3% | $213M-2.3% | $218M+18.5% | $184M— | —— | |
| Specialty Diagnostics | -$181M+1.1% | -$183M-8.3% | -$169M+4.5% | -$177M— | —— | |
| Selling, general and administrative expenses by Business | ||||||
| Analytical Instruments | $1.24B0.0% | $1.24B-1.0% | $1.26B-0.2% | $1.26B— | —— | |
| Laboratory Products and Biopharma Services | $2.4B+0.4% | $2.39B+1.3% | $2.36B-0.3% | $2.37B— | —— | |
| Life Sciences Solutions | $1.94B+1.5% | $1.91B+2.3% | $1.87B-0.3% | $1.87B— | —— | |
| Specialty Diagnostics | $714M+0.8% | $708M0.0% | $708M-0.4% | $711M— | —— | |
| Research and development expenses by Business | ||||||
| Analytical Instruments | $575M+0.3% | $573M+0.2% | $572M+1.8% | $562M— | —— | |
| Laboratory Products and Biopharma Services | $58M+3.6% | $56M-1.8% | $57M-3.4% | $59M— | —— | |
| Life Sciences Solutions | $545M-1.4% | $553M-0.5% | $556M-0.9% | $561M— | —— | |
| Specialty Diagnostics | $177M-0.6% | $178M-2.2% | $182M-1.1% | $184M— | —— | |
| Purchases of property, plant and equipment by Business | ||||||
| Analytical Instruments | $116M-6.5% | $124M+17.0% | $106M-0.9% | $107M— | —— | |
| Laboratory Products and Biopharma Services | $1.06B+5.4% | $1.01B-3.5% | $1.04B+13.0% | $921M— | —— | |
| Life Sciences Solutions | $129M-15.1% | $152M+4.1% | $146M+3.5% | $141M— | —— | |
| Specialty Diagnostics | $130M+1.6% | $128M-7.2% | $138M+6.2% | $130M— | —— | |
| Depreciation of property, plant and equipment by Business | ||||||
| Analytical Instruments | $106M+1.9% | $104M+1.0% | $103M+1.0% | $102M— | —— | |
| Laboratory Products and Biopharma Services | $618M+2.3% | $604M-3.5% | $626M-9.3% | $690M— | —— | |
| Life Sciences Solutions | $262M+4.4% | $251M+6.4% | $236M+1.7% | $232M— | —— | |
| Specialty Diagnostics | $93M+2.2% | $91M-9.0% | $100M-5.7% | $106M— | —— | |
| Consolidated revenues by Product | ||||||
| Consumables | $19.03B+2.0% | $18.66B+2.8% | $18.16B+1.7% | $17.86B+1.4% | $17.61B+0.1% | |
| Instruments | $7.23B-1.0% | $7.3B-0.4% | $7.33B+0.6% | $7.29B-2.1% | $7.45B0.0% | |
| Service revenues | $18.94B+1.9% | $18.59B+1.9% | $18.25B+1.0% | $18.07B+1.3% | $17.84B0.0% | |
| Consolidated revenues by Geography | ||||||
| Asia-Pacific | $8.18B+1.0% | $8.1B+0.9% | $8.03B+1.1% | $7.94B-0.6% | $7.99B+0.4% | |
| Europe | $12.16B+2.8% | $11.83B+4.2% | $11.35B+2.9% | $11.03B+1.5% | $10.86B0.0% | |
| North America | $23.23B+0.8% | $23.03B+1.1% | $22.79B+0.4% | $22.69B+0.9% | $22.5B0.0% | |
| Other regions | $1.63B+2.2% | $1.6B+1.5% | $1.57B+1.2% | $1.56B+0.3% | $1.55B-0.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Thermo Fisher Scientific break its business down?
- Thermo Fisher Scientific (TMO) reports consolidated revenues by business across 4 parts — Analytical Instruments, Laboratory Products and Biopharma Services, Life Sciences Solutions and Specialty Diagnostics. Each is extracted from the segment footnotes and tracked over time.
- Where does Thermo Fisher Scientific's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Thermo Fisher Scientific's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
